AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesInformation ScienceHealth Care
CyclophosphamidePhosphoramide MustardsBone Marrow PurgingAmifostineTransplantation, AutologousAntineoplastic Combined Chemotherapy ProtocolsInjections, SpinalLeukemiaAntineoplastic AgentsAldehyde DehydrogenaseBone MarrowVincristineDoxorubicinAntineoplastic Agents, AlkylatingDrug SynergismPrednisoneHematopoietic Stem CellsImmunosuppressive AgentsMethotrexatePulse Therapy, DrugDrug Administration ScheduleEtoposideEpirubicinCombined Modality TherapyBusulfanThiotepaTreatment OutcomePrednisoloneBreast NeoplasmsRemission InductionAntibodies, Monoclonal, Murine-DerivedFluorouracilLeukopeniaVidarabineBone Marrow TransplantationGranulocyte Colony-Stimulating FactorLymphoma, Non-HodgkinDisease-Free SurvivalMethylprednisoloneCystitisAdministration, MetronomicWhole-Body IrradiationHematopoietic Stem Cell TransplantationChemotherapy, AdjuvantDose-Response Relationship, DrugDrug Therapy, CombinationSurvival AnalysisCarmustineTransplantation ConditioningSurvival RateMelphalanImmunosuppressionAzathioprineWegener GranulomatosisLupus NephritisMesnaIfosfamideCisplatinTime FactorsNeutropeniaChlorambucilAcroleinMitoxantroneFollow-Up StudiesRecurrenceBleomycinTransplantation, HomologousAlkylating AgentsHematopoietic Stem Cell MobilizationLeukocyte CountProcarbazineAnemia, AplasticDexamethasoneCytarabinePaclitaxelLymphoma, Large B-Cell, DiffuseAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisCarboplatinNeoplasm StagingInfusions, IntravenousLeukemia, Lymphocytic, Chronic, B-CellPrognosisGraft vs Host DiseaseMicroscopic PolyangiitisSpleenThrombocytopeniaAntibodies, MonoclonalVomitingMultiple MyelomaAdministration, OralNeoadjuvant TherapyProspective StudiesDrug EvaluationMyeloablative AgonistsTaxoidsLymphoma, FollicularBiotransformationCarcinoma, Small CellAntilymphocyte SerumInjections, Intravenous
OxazaphosphorineTumors7654ASTAPediatricLysineTherapeuticTreatmentCancer
Oxazaphosphorine4
  • Mafosfamide (INN) is an oxazaphosphorine (cyclophosphamide-like) alkylating agent under investigation as a chemotherapeutic. (wikipedia.org)
  • 11. Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide). (nih.gov)
  • 13. Antitumoral activity of the oxazaphosphorine derivative, mafosfamide-cyclohexylamine salt (ASTA 7557) on a murine ovarian reticular cell sarcoma and its subline resistant to cyclophosphamide. (nih.gov)
  • 15. Antiproliferative activity of 2-[N, N-bis-(2-chloroethyl)-amino]-4-[2-sulfonato-ethylthio]-tetrah ydr o-2H-1 , 3,2-oxazaphosphorine-2-oxide cyclohexamine (ASTA Z 7557, INN mafosfamide) against human and murine tumor cells in vitro. (nih.gov)
Tumors4
  • 3. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). (nih.gov)
  • 7. Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors. (nih.gov)
  • 17. Antineoplastic activity of ASTA Z 7557 (NSC-345842, INN mafosfamide) on transplantable murine tumors. (nih.gov)
  • 19. Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. (nih.gov)
76542
  • 8. New application of a stabilized active cyclophosphamide derivative (mafosfamide, ASTA Z 7654)--immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug. (nih.gov)
  • 18. In vitro chemosensitivity of leukemic progenitor cells (AML-CFU) to a combination of mafosfamide lysine (ASTA-Z 7654) and etoposide (VP16-213). (nih.gov)
ASTA3
  • 1. Phase-I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase-I data on mafosfamide-lysine. (nih.gov)
  • 5. Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice. (nih.gov)
  • 12. Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide. (nih.gov)
Pediatric1
  • Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. (medkoo.com)
Lysine2
Therapeutic1
  • 4. Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma. (nih.gov)
Treatment1
  • Treatment with 1.0 microM imatinib, 60 microg/ml mafosfamide and 14 days of culture with cytokines eliminated BCR-ABL(+) cells from chronic phase CML patient aphereses, while preserving normal progenitors. (nih.gov)
Cancer1
  • We previously performed a genome-wide association study (GWAS) for neutropenia events in women with breast cancer who were treated with 5-fluorouracil, epirubicin and cyclophosphamide and recruited to the SUCCESS-A trial. (nih.gov)